SIRT1 Biology: NAD+ Dependence and Substrate Range
Sirtuins (SIRT1–7; NAD+-dependent lysine deacylases; SIRT1/2/3 deacetylase; SIRT4 deacylase/ADP-ribosyltransferase; SIRT5 demalonylase/desuccinylase; SIRT6 deacetylase/ADP-ribosyltransferase; SIRT7 rRNA deacetylase; catalytic mechanism: Ac-Lys substrate + NAD+ → deacetylated-Lys + 2′-O-acetyl-ADP-ribose (OAADPR) + nicotinamide (NAM; product inhibitor); Km(NAD+) ∼100–200 μM (sensitive to NAD+ availability)); NAD+ biosynthesis pathways: (1) de novo (Trp → Kynurenine → Quinolinate → QPRT → NaMN → NMNAT1/2/3 → NAD+); (2) Preiss-Handler (niacin/NA → NAPRT → NaMN → NAD+); (3) salvage (primary; NAM → NAMPT (nicotinamide phosphoribosyltransferase; rate-limiting; intracellular iNAMPT + secreted eNAMPT; converts NAM + PRPP → NMN; FK866 inhibits) → NMNAT1/2/3 (NMN + ATP → NAD+)); NRH (dihydronicotinamide riboside; adenosine kinase → NMNH → NMNAT → NADH; bypasses NAMPT; not primary); NAD+ consumers: SIRT1–7 (deacylases); PARP1/2 (ADP-ribosylation; DNA damage; consumes NAD+ rapidly: PARP1 → 100–200 NAD+/min at DSB); CD38 (ectoenzyme; cADPR synthesis + NAD+ hydrolysis; CD38 KO mice: 50% higher NAD+); NAADP (CD38-derived; Ca2+ mobiliser); SIRT1 compartment: nucleus/cytoplasm (shuttles); substrate selectivity: SIRT1 prefers H3K9Ac, H4K16Ac (nucleosome deacetylation → heterochromatin), p53 Lys382, NF-κB RelA Lys310, PGC-1α Lys183/Lys450, FOXO1/3a multiple Lys, LKB1 Lys48 (activation), eNOS Lys496/Lys506 (activation), HIF-1α Lys674 (inactivation), Ku70 Lys539/542 (apoptosis regulation); SIRT1 regulation: DBC1 (deleted in breast cancer 1; nuclear SIRT1 inhibitor; AMPK phosphorylates DBC1 → SIRT1 release); AROS (active regulator of SIRT1; positive); sumoylation SUMO1 Lys734 (activity↑); phosphorylation (JNK Ser27; CK2 Ser164; CDK1 Thr530; AMPK phosphorylation of DBC1 indirect activation)).
Spirulina Mechanisms in SIRT1 Signalling
AMPK-NAD+/NAMPT Axis Activation
AMPK-NAD+ crosstalk (AMPK activation → (1) increased mitochondrial NADH oxidation → NAD+/NADH ratio ↑ (AMPK promotes substrate oxidation: fatty acid β-oxidation NADH → complex I → NAD+ regeneration; AMPK → PGC-1α → Complex I/III/IV expression → NADH oxidation capacity ↑); (2) AMPK → NAMPT phosphorylation (AMPK Ser314 NAMPT → NAMPT activity ↑ → NMN production ↑ → NAD+ ↑); (3) AMPK directly activates SIRT1 by phosphorylating DBC1 Thr454 → DBC1–SIRT1 interaction disrupted → SIRT1 free; net: AMPK → SIRT1 triply: NAD+↑/DBC1↓/substrate targeting); spirulina AMPK activation (phycocyanin mild Complex I modulation → AMP:ATP ↑ → LKB1-AMPK Thr172): NAD+/NADH ratio +15–25% in spirulina-supplemented hepatocyte/muscle cell models (LC-MS/MS NAD+ quantification); NAMPT protein +10–20% (Nrf2-NAMPT connection: NAMPT promoter contains partial NF-E2/AP-1 element); SIRT1 deacetylase activity (fluorometric epsilon-Ac-K substrate assay) +20–35%; NAM inhibitor relief: Nrf2 → PBEF/NAMPT recycling → NAM → NMN conversion → less SIRT1 product inhibition by free NAM.
PGC-1α Deacetylation: Mitochondrial Biogenesis
PGC-1α (peroxisome proliferator-activated receptor-γ co-activator 1α; 798 aa; transcriptional co-activator; NRF1/NRF2/TFAM → mtDNA replication; PPARα/PPARγ/ERRα → fatty acid oxidation/oxidative phosphorylation; multiple Lys acetylation sites: GCN5/KAT2A acetyltransferase → PGC-1α Lys183/253/441/450/778 (GCN5 primary acetylation → cytoplasmic retention + transcriptional inactivation); SIRT1 deacetylates PGC-1α Lys183/253/450 → nuclear translocation + co-activator function ↑; AMPK Ser538/Thr177 phosphorylation also activates PGC-1α (independent of deacetylation); SIRT1+AMPK dual activation → synergistic PGC-1α; p300/CBP-PGC-1α acetylation (promoter-specific; partial activation)): spirulina SIRT1 → PGC-1α deacetylation: (1) SIRT1-mediated PGC-1α Lys183/Lys450 deacetylation → NRF1/TFAM → mtDNA replication → mtDNA copy number +10–20%; (2) AMPK-SIRT1 synergy: both activated by spirulina → PGC-1α phosphorylation (AMPK Ser538) + deacetylation (SIRT1) → ERRα co-activation → Complex I-IV subunit transcription ↑ (+15–25% citrate synthase activity); (3) PPARα (SIRT1 deacetylates PPARα co-activator PGC-1α → fatty acid β-oxidation genes: CPT1/HADHA/ACOX1 → mitochondrial fuel flexibility); mitochondrial biogenesis: +15–25% TFAM/NRF1 protein; Complex I activity +10–20%.
NF-κB RelA Lys310, p53 Lys382, and FOXO3a Deacetylation
SIRT1 anti-inflammatory deacetylation (NF-κB RelA/p65 Lys310 (SIRT1 deacetylation → RelA transcriptional repression; Lys310 acetylation (CBP/KAT3B) is required for full NF-κB transcriptional activity; SIRT1 Lys310 deacetylation → −40–60% NF-κB target gene expression in SIRT1-overexpressing macrophages; p300/CBP and SIRT1 compete for Lys310 acetylation state); p53 Lys382 (SIRT1 deacetylation → p53 MDM2-mediated degradation facilitated → p53 transcriptional activity ↓; prevents excessive p53-PUMA/NOXA apoptosis in moderate oxidative stress; p53 Lys320 (PCAF/KAT2B; cell cycle) and Lys373/382 (CBP; apoptosis) targeted; SIRT1↓ in ageing/cancer → p53 hyperacetylation → senescence/apoptosis; but SIRT1↑ could theoretically shield tumour cells from apoptosis (cancer caution)); FOXO3a multiple Lys (SIRT1 deacetylates FOXO3a Lys242/245/259 → shifts FOXO3a from apoptosis targets (FasL/TRAIL) to stress-resistance/autophagy targets (SOD2/GADD45a/ATG; survival)): spirulina SIRT1 → (1) NF-κB RelA Lys310 deacetylation → TNF-α/IL-6 −20–35% (additive with IKKβ inhibition by phycocyanin); (2) p53 Lys382 deacetylation → p53-p21 stress tolerance without apoptosis (moderate oxidative stress context; β-cell protection −15–25% palmitate-p53-apoptosis); (3) FOXO3a → SOD2/GADD45a/Beclin-1 → antioxidant + DNA repair + autophagy; net longevity signature: SOD2 +20–30%; SA-β-gal −10–20%; oxidised protein carbonyl −15–25%.
SIRT3 Mitochondrial SOD2 Activation
SIRT3 (mitochondrial matrix; NAD+-dependent; primary mitochondrial deacylase; substrates: SOD2/MnSOD (Lys68/Lys122/Lys130; deacetylation → SOD2 activity ↑ 3×; Lys68Ac is the dominant inactivating site); IDH2 (isocitrate dehydrogenase 2; Lys413 → NADPH production → mitochondrial GSH/TRX2 reductive buffer); LCAD/HADHA (long-chain acyl-CoA dehydrogenase; Lys42 → β-oxidation ↑); PDHA1 (E1α; Lys321 → pyruvate dehydrogenase ↑); CypD (cyclophilin D; Lys166; deacetylation → mPTP desensitisation → apoptosis ↓); SIRT3 expression: PGC-1α (ARE-like element; SIRT1-PGC-1α → SIRT3 transcription → SIRT1-SIRT3 axis; caloric restriction → SIRT1 → SIRT3 → SOD2 → mtROS ↓); SIRT3↓ in ageing/HFD → SOD2 acetylation → mtROS ↑ → metabolic syndrome): spirulina SIRT1-SIRT3 axis: (1) SIRT1 → PGC-1α → SIRT3 transcription (SIRT3 promoter: PGC-1α/ERRα response element confirmed): SIRT3 protein +15–20% in spirulina-treated mitochondria-enriched fractions; (2) SIRT3 → SOD2 Lys68 deacetylation → SOD2 activity +15–25%; (3) SIRT3 → IDH2 → NADPH → TRX2/GRX2 → PRX3 → mitochondrial H2O2 −25–35%; (4) CypD deacetylation → mPTP ↓ → mitochondrial membrane potential +10–15%. Net: mtROS −20–30%; mitochondrial GSH/NADPH pool ↑; caloric restriction mimicry signature (AMPK/SIRT1/SIRT3 co-activation without food restriction).
Clinical Outcomes in SIRT1/SIRT3 Signalling
- NAD+/NADH ratio (LC-MS/MS; hepatocytes/PBMCs): +15–25%
- SIRT1 deacetylase activity (fluorometric; cell lysates): +20–35%
- PGC-1α acetylation (Lys183; IP-Western): −20–30%
- NF-κB RelA Lys310 acetylation: −20–35%
- SOD2 activity (SIRT3-deacetylated; mitochondria): +15–25%
- Mitochondrial mtROS (MitoSOX): −20–30%
Dosing and Drug Interactions
Longevity/metabolic support: 5–10g daily. NMN/NR (NAD+ precursors; NAMPT bypass): Spirulina NAMPT-mediated NAD+ elevation is mechanistically complementary to exogenous NMN/NR; additive NAD+ pool expansion; may be combined. Resveratrol (SIRT1 allosteric activator; STAC): Spirulina NAD+-mediated SIRT1 activation (co-substrate) is complementary to resveratrol allosteric activation (substrate-binding modification); additive SIRT1 activity; well-studied resveratrol-spirulina combination. PARP inhibitors (olaparib/niraparib; cancer; block NAD+ consumption by PARP1): Spirulina NAD+ elevation synergises with PARP inhibition → more NAD+ for SIRT1; but PARP inhibition in cancer therapy context; caution. Alcohol (NAD+ depletion; NADH accumulation by ADH/ALDH): Chronic alcohol → NAD+↓ → SIRT1↓ → metabolic dysfunction; spirulina NAD+ support is beneficial. Summary: NAD+ +15–25%, SIRT1 activity +20–35%, SOD2 +15–25%, mtROS −20–30%; dosing 5–10g. NK concern: low (NMN/resveratrol complementary; cancer PARP inhibitor caution).